Stock LUCD LUCID DIAGNOSTICS INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Lucid Diagnostics Inc.

Equities

LUCD

US54948X1090

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
0.9159 USD -1.52% Intraday chart for Lucid Diagnostics Inc. +1.20% -35.04%
May. 13 Transcript : Lucid Diagnostics Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13 Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
PAVmed Provides Business Update and First Quarter 2024 Financial Results
PR
Transcript : Lucid Diagnostics Inc., Q1 2024 Earnings Call, May 13, 2024
Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Lucid Diagnostics Inc. Announces Legacy Esophageal Cell Collection Device Subject of Class II FDA Recall
CI
Lucid Diagnostics Inc. announced that it has received $11.634 million in funding
CI
Lucid Diagnostics Inc. announced that it expects to receive $11.634 million in funding
CI
Lucid Diagnostics : Corporate Presentation - March 2024
PU
Cantor Fitzgerald Trims Price Target on Lucid Diagnostics to $3 From $3.80, Maintains Overweight Rating
MT
PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results
PR
Transcript : Lucid Diagnostics Inc., Q4 2023 Earnings Call, Mar 26, 2024
Lucid Diagnostics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Lucid Diagnostics Inc. Announces Positive Data from the First Prospective Clinical Validation Study of Esoguard Esophageal Precancer Testing in A Screening Population
CI
Lucid Diagnostics Inc. announced that it has received $18.16 million in funding
CI
Lucid Diagnostics Provides Update Regarding World Trade Center Health Program
AQ
Lucid Diagnostics Executes Contract to Provide EsoGuard Esophageal Precancer Testing as a Covered Benefit for 9/11 Responders and Survivors
AQ
Lucid Diagnostics Inc. Executes Contract to Provide Esoguard® Esophageal Precancer Testing as A Covered Benefit for 9/11 Responders and Survivors
CI
Transcript : Lucid Diagnostics Inc. - Analyst/Investor Day
Lucid Diagnostics Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
PR
Lucid Diagnostics Inc. and Pavmed Inc. Announces Peer-Reviewed Publication of Positive Results from Three Clinical Utility Studies
CI
Transcript : Lucid Diagnostics Inc., Q3 2023 Earnings Call, Nov 14, 2023
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LUCD Stock
  4. News Lucid Diagnostics Inc.